Regina Rouse
Family · West Columbia, SCNPI 1487938825
Payments from drug & device makers
Across 65 payments — averaging $108.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$6K
- Novo Nordisk$214
- AbbVie$193
- Novartis$113
- Bayer$107
- Axsome Therapeutics, Inc.$33
- plus $365 from 15 others
What the payments were for
- Consulting fees$3,81854%
- Travel & lodging$1,64623%
- Food & beverage$1,55722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $5,996 |
| Novo Nordisk | 6 | $214 |
| AbbVie | 15 | $193 |
| Novartis | 5 | $113 |
| Bayer | 7 | $107 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Amgen | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| Fidia Pharma USA Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Medtronic | 2 | $30 |
| Abbott | 2 | $30 |
| Merck | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Stryker | 1 | $22 |
| Insulet Corporation | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$115
How this compares
$7,021 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $389 |
| Fluticasone Propionate | 12 | $230 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $197 |
| Doxycycline Hyclate | 18 | $145 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $103 |
| Prednisone | 22 | $85 |
Paid to pharmacies, not to this prescriber.
Other family in West Columbia
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.